Proteomic changes in renal cancer and co‐ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect

  title={Proteomic changes in renal cancer and co‐ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect},
  author={Richard D. Unwin and Rachel A. Craven and Patricia Harnden and Sarah Hanrahan and Nicholas F. Totty and Margaret A. Knowles and Ian Eardley and Peter J. Selby and Rosamonde E. Banks},
Renal cell carcinoma (RCC) is the tenth most common cancer although the incidence is increasing. The main clinical problems stem from the relatively late presentation of many patients due to the often asymptomatic nature of the illness, and the relative insensitivity of metastatic disease to conventional chemotherapy and radiotherapy. Despite increasing knowledge of some of the genetic changes underlying sporadic renal cancer such as those involving the Von Hippel Lindau (VHL) gene, many of the… Expand
Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma
Using proteome‐based strategies, a number of RCC‐associated markers either over‐expressed or down‐regulated in tumor lesions in comparison to the normal epithelium have been identified which have been implicated in tumorigenesis, but never linked to the initiation and/or progression of R CC. Expand
Pathway analysis of kidney cancer using proteomics and metabolic profiling
Extensive pathway and network analysis allowed for the discovery of highly significant pathways from a set of clear cell RCC samples, and it is demonstrated how the knowledge of networks, processes, and pathways altered in kidney cancer may be used to influence the choice of optimal therapy. Expand
Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.
An extensive analysis of human RCC tissue employing combined grade-dependent proteomics and metabolomics analysis found that the glutamine metabolism pathway acts to inhibit reactive oxygen species, as evidenced by an upregulated glutathione pathway, whereas the β-oxidation pathway is inhibited, leading to increased fatty acylcarnitines. Expand
Grade-dependent Proteomics Characterization of Kidney Cancer*S
It is shown that changes among many biochemical processes and pathways are strongly grade-dependent with the glycolytic and amino acid synthetic pathways highly represented. Expand
Understanding and managing renal cell carcinoma: can proteomic studies contribute to clinical practice?
The challenge now is to build on these initial efforts, focusing particularly on interrogating the less readily accessible, lower abundance proteome and implementing large-scale validation studies to develop potential markers, antigens and targets and facilitate translation of suitable findings into the clinic. Expand
Candidate biomarkers in renal cell carcinoma
The comprehensive analysis of the results expands the knowledge about the pathophysiology of RCC in particular of the most prominent clear cell subtype by providing information on the differentially expressed proteins, their regulation status in RCC compared to normal kidney epithelium next to additional information on MHC‐presented T cell epitopes and on serological targets. Expand
Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma
There are no serum biomarkers for the accurate diagnosis of clear cell renal cell carcinoma (ccRCC). Diagnosis and decision of nephrectomy rely on imaging which is not always accurate. Non-invasiveExpand
Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma?
Global, untargeted comparative analysis of RCC vs tumor adjacent renal epithelium (NN) samples by high throughput analyses both at the transcriptome and proteome level have identified signatures, which might further clarify the molecular differences of R CC subtypes and might allow the identification of suitable therapeutic targets and diagnostic/prognostic biomarkers. Expand
Whole cell profiling and identification of galectin‐1 as a potential marker of renal cell carcinoma
Investigation of expression difference mapping analysis of whole cell proteins from renal cell carcinoma (RCC) cell lines using ProteinChip technology established, for the first time, the identification of three forms of galectin‐1 as potential RCC marker. Expand
Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications.
This review will begin with a brief summary of normal cellular bioenergetic pathways, which will be followed by a description of the characteristic metabolism of glucose and lipids in clear-cell RCC cells and its clinical implications. Expand